All News

Found 100 articles

• Neoleukin Therapeutics Announces Multiple Presentations at American Association for Cancer Research (AACR) Annual Meeting

  3/8/2022

  Neoleukin Therapeutics, Inc., “Neoleukin”, a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, announced three presentations at the upcoming American Association for Cancer Research Annual Meeting taking place April 8-13, 2022 in New Orleans, Louisiana.

• Neoleukin Therapeutics Announces Year End 2021 Financial Results and Corporate Update

  3/1/2022

  Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced financial results and a corporate update for the year ended December 31, 2021.

• Neoleukin Therapeutics to Host 2021 Financial Results Conference Call and Webcast on March 1, 2022

  2/22/2022

  Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), today announced it will report full year 2021 financial results on Tuesday, March 1, 2022 after the close of financial markets and then host a conference call and live audio webcast to discuss these results and provide a corporate update.

• Neoleukin Therapeutics to Present at Guggenheim Healthcare Talks 2022 Oncology Conference

  2/3/2022

  Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will participate in a fireside chat at the Guggenheim Healthcare Oncology Talks 2022 Oncology Conference.

• Expansion Therapeutics Appoints Gary Bridger, Ph.D., to Its Board of Directors

  1/19/2022

  Expansion Therapeutics, Inc. today announced the appointment of Gary Bridger, Ph.D., to its Board of Directors, serving as an independent director.

• 

  Clinical Catch-Up: January 10-14

  1/17/2022

  Heading into the middle of January, companies announced plenty of new clinical trial news. Here’s a look.

• Neoleukin Therapeutics Announces Clinical Collaboration with Merck to Evaluate NL-201 in Combination with KEYTRUDA® (pembrolizumab)

  1/10/2022

  Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced a clinical trial collaboration and supply agreement with Merck (known as MSD outside the United States and Canada).

• Neoleukin Therapeutics Presenting at H.C. Wainwright BIOCONNECT Virtual Conference

  1/10/2022

  Neoleukin Therapeutics, Inc. announced that Jonathan Drachman, M.D., Chief Executive Officer, will present at the H.C. Wainwright BIOCONNECT Virtual Conference taking place January 10-13, 2022.

• Neoleukin Therapeutics Announces Preclinical Data Highlighting Activity of NL-201 in Hematologic Malignancies at 63rd American Society of Hematology Annual Meeting (ASH 2021)

  12/11/2021

  Neoleukin Therapeutics, Inc., “Neoleukin”, a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, announced the presentation of preclinical data on NL-201 in multiple myeloma at the 63rd American Society of Hematology Annual Meeting and Exposition taking place virtually and in person December 11-14, 2021.

• Neoleukin Therapeutics Presents NL-201 Preclinical Data at Society for Immunotherapy of Cancer’s 36th Annual Meeting (SITC 2021)

  11/12/2021

  Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), today announced the presentation of new preclinical data on NL-201, an alpha-independent, de novo-designed IL-2 and IL-15 dual agonist, at the Society for Immunotherapy of Cancer’s 36th Annual Meeting (SITC 2021).

• ImCheck Provides Promising Updated Patient Response Data from the Phase I/IIa EVICTION Trial with ICT01 at SITC Meeting 2021

  11/12/2021

  ImCheck Therapeutics provided updated patient response data from its ongoing EVICTION Phase I/IIa clinical trial of its lead candidate ICT01 in an oral presentation at the Society for Immunotherapy of Cancer (SITC) Meeting 2021.

• Neoleukin Therapeutics to Present at Upcoming Investor Conferences

  11/9/2021

  Neoleukin Therapeutics, Inc., today announced that management will participate in two upcoming investor conferences. Presentation Details: Event: Stifel 2021 Virtual Healthcare Conference Date: Tuesday, November 16, 2021 Time: 3:20 to 3:50 p.m. EST

• Neoleukin Therapeutics Announces Third Quarter 2021 Financial Results and Corporate Update

  11/4/2021

  Neoleukin Therapeutics, Inc., today announced financial results and a corporate update for the third quarter ended September 30, 2021.

• Neoleukin Therapeutics Announces Multiple Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer’s 36th Annual Meeting (SITC 2021)

  10/1/2021

  Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the acceptance of four abstracts to be presented at the upcoming Society for Immunotherapy of Cancer’s 36th Annual Meeting

• 

  IDWeek Presentations Highlight Continued Response to COVID-19

  9/29/2021

  As the 10th annual IDWeek (Infectious Disease Week) Conference begins, treatments aimed at COVID-19 will certainly dominate the program.

• Neoleukin Therapeutics Announces Oral Presentation at IDWeek 2021 of Data Demonstrating that NL-CVX1, a Computationally Designed De Novo Protein, Can Block Infection by SARS-CoV-2 Viral Variants of Concern

  9/29/2021

  Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced new data highlighting the ability of its de novo protein decoy, NL-CVX1, to block SARS-CoV-2 infection in certain viral variants.

• Neoleukin Therapeutics Announces Appointment of Bill Arthur, Ph.D., as Vice President and Head of Research

  9/9/2021

  Neoleukin Therapeutics, Inc., today announced the appointment of Bill Arthur, Ph.D., as Vice President and Head of Research.

• Neoleukin Therapeutics to Present at H.C. Wainwright 23rd Annual Global Investment Conference

  9/7/2021

  Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will present a corporate overview during the H.C. Wainwright 23rd Annual Global Life Sciences Conference.

• Neoleukin Therapeutics Announces Second Quarter 2021 Financial Results & Provides Corporate Update

  8/5/2021

  Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced financial results for the second quarter ended June 30, 2021 and provided a midyear corporate update.

• Neoleukin Therapeutics to Participate in Canaccord Genuity 41st Annual Growth Conference

  8/4/2021

  Neoleukin Therapeutics, Inc., today announced that Jonathan Drachman, M.D., Chief Executive Officer, will participate in a fireside chat at the virtual Canaccord Genuity 41 st Annual Growth Conference on Wednesday, August 11, 2021 at 8:00 a.m. Eastern Time.